Express | Sanyou Biopharmaceuticals and Dragon Sail Pharmaceutical jointly building a one-stop antibody drug R&D service platform.
At the groundbreaking ceremony
of Dragon Sail Pharmaceutical - Lin'gang Production Base and the launch conference
of NONCROS™ brand held in Lin'gang, held on March 22, Sanyou Biopharmaceuticals and Dragon Sail
Pharmaceutical jointly announced their effort in building a one-stop antibody
drug R&D service platform.
At this ceremony, held in
Shanghai Lin'gang Fengxian Park. Mr. Guojun Lang, Chairman/CEO of Sanyou
Biopharmaceuticals, attended and signed the strategic cooperation agreement.
△Mr. Xun Zou, Executive
Director of Dragon Sail Pharmaceutical, delivered a speech.
At the groundbreaking ceremony
and press conference, Mr. Xun Zou, Executive Director of Dragon Sail
Pharmaceutical, introduced the construction goal and planning of the
industrialization base for production and sales of clinical samples and
marketed products of high-end monoclonal antibody drugs of Dragon Sail
Pharmaceutical. After completion of the industrialization base, the service
scope will cover process development, customized contract production, quality
research, registration, declaration, etc. In compliance with the requirements
of multi-product co-production in the most efficient and cost-effective manner,
and with the maximum production scale up to 12,000 L, the NONCROS™ non-cross
antibody production platform will be one of the largest monoclonal antibody
production bases in Shanghai.
Mr. Xufei Wang, President of Guilin Sanjin Pharmaceutical, said "Guilin Sanjin Pharmaceutical will offer its full support in terms of capital, management and channels to boost the rapid industrialization development of monoclonal antibody in Dragon Sail Pharmaceutical.
At the conference, Mr. Guoping Zhao, academician of The Chinese Academy of Sciences, Mr. Shaoxiong Chen, Secretary General of Shanghai Biopharmaceutics Industry Association, Dr. Peizhi Luo, Chairman and President of Tianyan Pharmaceutical, Mr. Rene Faber, Executive Director of Sartorius, Ms. Hongyan Xie, Senior President of GEHC Strategic Customer Relations, and Mr. Johnny Han, General Manager of COCKRAM (China) all conveyed their congratulations and delivered inspiring speeches.
△ Mr. Guojun Lang, CEO of Sanyou Biopharmaceuticals (left) and Mr. Xun Zou, Executive Director of Dragon Sail Pharmaceutical (right)
At the groundbreaking ceremony,
Dragon Sail Pharmaceutical signed respective strategic cooperation agreements
with Tianyan Pharmaceutical (Suzhou) Co., Ltd., Shanghai Maiji Biotechnology
Co., Ltd. and Sanyou Biopharmaceuticals (Shanghai) Co., Ltd.
Committed to the early R&D
service of innovative antibody drugs, Sanyou Biopharmaceutical has strong
R&D strength with the completion of its internationally advanced innovative
antibody R&D technology platform, which provides high-throughput project
incubation and phase technical services for tumors, autoimmune diseases, etc. Dragon Sail pharmaceutical has a complete
process development and production platform of monoclonal antibody drugs, which
can be used for large-scale production of monoclonal antibody drugs in
accordance with the GMP requirements.
This cooperation with Dragon
Sail Pharmaceutical integrates the early R&Dtechnology,
platform advantage of Sanyou Biopharmaceuticals with Dragon Sail
Pharmaseutical’s rich experience in pharmaceutical process R&D. This complementary and compatible integration
of these two companies will benefit patients around the world with a wider
promotion of the R&D process of innovative antibody drugs!
About Dragon Sail Pharmaceutical
Formed in 2016 in Shanghai, Dragon
Sail Pharmaceutical (Shanghai) Co., Ltd., is a wholly-owned subsidiary invested
by the publicly-traded company Guilin Sanjin Pharmaceutical Co., Ltd. Attached to Dragon B oat Biopharmaceutical
R&D Center established in 2005, Dragon Sail Pharmaceutical has a total investment
of RMB 690 million, and is in process of building an industrialization base of
R&D, clinical praciton, production and sales of monoclonal antibody drugs
against tumors in Fengxian Lin'gang Intelligent Manufacturing Park. With a
production scale of 12,000 L and an estimated annual sales of more than RMB 1.0
billion upon completion, Dragon Sail Pharmaceutical will be one of Shanghai's
largest monoclonal antibody production bases with GMP-compliant